Home Healthcare Biotechnology Liquid Biopsy Market

Liquid Biopsy Market Size, Share & Trends Analysis Report By Product and Services (Kits and Reagents, Platforms and Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA]), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer), By End-User (Hospitals and Laboratories, Government and Academic Research Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Liquid Biopsy Market, By Product and Services 2022-2034 (USD MILLION/ Units)
    1. Kits and Reagents
    2. Platforms and Instruments
    3. Services
  2. Liquid Biopsy Market, By Circulating Biomarker 2022-2034 (USD MILLION/ Units)
    1. Circulating Tumor Cells
    2. Extracellular Vesicles
    3. Circulating Tumor DNA [ctDNA]
  3. Liquid Biopsy Market, By Cancer Type 2022-2034 (USD MILLION/ Units)
    1. Lung Cancer
    2. Breast Cancer
    3. Colorectal Cancer
    4. Prostate Cancer
    5. Liver Cancer
  4. Liquid Biopsy Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals and Laboratories
    2. Government and Academic Research Centers
  5. Regional Liquid Biopsy Market
    1. North America
      1. North America Liquid Biopsy Market By Product and Services 2022-2034 (USD MILLION/ Units)
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
      2. North America Liquid Biopsy Market By Circulating Biomarker 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells
        2. Extracellular Vesicles
        3. Circulating Tumor DNA [ctDNA]
      3. North America Liquid Biopsy Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Liver Cancer
      4. North America Liquid Biopsy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Laboratories
        2. Government and Academic Research Centers
      5. U.S.
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      6. Canada
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
    2. Europe
      1. Europe Liquid Biopsy Market By Product and Services 2022-2034 (USD MILLION/ Units)
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
      2. Europe Liquid Biopsy Market By Circulating Biomarker 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells
        2. Extracellular Vesicles
        3. Circulating Tumor DNA [ctDNA]
      3. Europe Liquid Biopsy Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Liver Cancer
      4. Europe Liquid Biopsy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Laboratories
        2. Government and Academic Research Centers
      5. U.K.
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      6. Germany
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      7. France
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      8. Spain
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      9. Italy
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      10. Russia
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      11. Nordic
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      12. Benelux
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      13. Rest of Europe
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
    3. APAC
      1. APAC Liquid Biopsy Market By Product and Services 2022-2034 (USD MILLION/ Units)
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
      2. APAC Liquid Biopsy Market By Circulating Biomarker 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells
        2. Extracellular Vesicles
        3. Circulating Tumor DNA [ctDNA]
      3. APAC Liquid Biopsy Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Liver Cancer
      4. APAC Liquid Biopsy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Laboratories
        2. Government and Academic Research Centers
      5. China
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      6. Korea
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      7. Japan
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      8. India
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      9. Australia
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      10. Taiwan
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      11. South East Asia
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      12. Rest of Asia-Pacific
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
    4. Middle East and Africa
      1. Middle East and Africa Liquid Biopsy Market By Product and Services 2022-2034 (USD MILLION/ Units)
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
      2. Middle East and Africa Liquid Biopsy Market By Circulating Biomarker 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells
        2. Extracellular Vesicles
        3. Circulating Tumor DNA [ctDNA]
      3. Middle East and Africa Liquid Biopsy Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Liver Cancer
      4. Middle East and Africa Liquid Biopsy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Laboratories
        2. Government and Academic Research Centers
      5. UAE
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      6. Turkey
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      7. Saudi Arabia
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      8. South Africa
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      9. Egypt
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      10. Nigeria
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      11. Rest of MEA
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
    5. LATAM
      1. LATAM Liquid Biopsy Market By Product and Services 2022-2034 (USD MILLION/ Units)
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
      2. LATAM Liquid Biopsy Market By Circulating Biomarker 2022-2034 (USD MILLION/ Units)
        1. Circulating Tumor Cells
        2. Extracellular Vesicles
        3. Circulating Tumor DNA [ctDNA]
      3. LATAM Liquid Biopsy Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Liver Cancer
      4. LATAM Liquid Biopsy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Laboratories
        2. Government and Academic Research Centers
      5. Brazil
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      6. Mexico
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      7. Argentina
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      8. Chile
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      9. Colombia
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
      10. Rest of LATAM
        1. Kits and Reagents
        2. Platforms and Instruments
        3. Services
        4. Circulating Tumor Cells
        5. Extracellular Vesicles
        6. Circulating Tumor DNA [ctDNA]
        7. Lung Cancer
        8. Breast Cancer
        9. Colorectal Cancer
        10. Prostate Cancer
        11. Liver Cancer
        12. Hospitals and Laboratories
        13. Government and Academic Research Centers
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.